Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Real-world Experience with Capmatinib in MET Exon 14-mutated Non-small Cell Lung Cancer (RECAP)

Autor: Illini, O., Fabikan, H., Swalduz, A., Krenbek, D., Vikstrom, A., Schumacher, M., Dudnik, E., Studnicka, M., Ohman, R., Wurm, R., Wannesson, L., Peled, N., Kian, W., Bar, J., Daher, S., Addeo, A., Rotem, O., Pall, G., Zer, A., Saad, A., Cufer, T., Sorotsky, H. G., Hashemi, S. M. S., Mohorcic, K., Stoff, R., Rovitsky, Y., Keren-Rosenberg, S., Winder, T., Weinlinger, C., Valipour, A., Hochmair, M. J.

Publikováno v: Illini, O, Fabikan, H, Swalduz, A, Krenbek, D, Vikstrom, A, Schumacher, M, Dudnik, E, Studnicka, M, Ohman, R, Wurm, R, Wannesson, L, Peled, N, Kian, W, Bar, J, Daher, S, Addeo, A, Rotem, O, Pall, G, Zer, A, Saad, A, Cufer, T, Sorotsky, H G, Hashemi, S M S, Mohorcic, K, Stoff, R, Rovitsky, Y, Keren-Rosenberg, S, Winder, T, Weinlinger, C, Valipour, A & Hochmair, M J 2022, ' Real-world Experience with Capmatinib in MET Exon 14-mutated Non-small Cell Lung Cancer (RECAP) ', Journal of Thoracic Oncology, vol. 17, no. 9, pp. S460-S460 .
Journal of Thoracic Oncology, 17(9), S460-S460. International Association for the Study of Lung Cancer

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::3edf4f818230f06efbece638823d2977
https://research.vumc.nl/en/publications/257aeb33-e1d5-4456-afd1-4318a67e7361

EP10.01-14 Efficacy and Safety of Nintedanib and Docetaxel in Patients with Lung Adenocarcinoma: A Multicenter Real-world Analysis

Autor: Jakopovic, M., Ljubicic, L., Janzic, U., Unk, M., Terglav, A.S., Mohorcic, K., Seiwerth, F., Bitar, L., Badovinac, S., Plestina, S., Samarzija, M.

Publikováno v: In Journal of Thoracic Oncology November 2023 18(11) Supplement:S607-S607

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Efficacy and safety of nintedanib and docetaxel in patients with previously treated lung non-squamous non-small cell lung cancer: a multicenter retrospective real-world analysis

Autor: Ljubicic Lidija, Janzic Urska, Unk Mojca, Terglav Ana Sophie, Mohorcic Katja, Seiwerth Fran, Bitar Lela, Badovinac Sonja, Plestina Sanja, Korsic Marta, Kukulj Suzana, Samarzija Miroslav, Jakopovic Marko

Publikováno v: Radiology and Oncology, Vol 57, Iss 3, Pp 397-404 (2023)

The standard first-line systemic treatment for patients with non-oncogene addicted advanced nonsquamous non-small cell lung cancer (NSCLC) is immunotherapy with immune checkpoint inhibitors (ICI) and/or chemotherapy (ChT). Therapy after failing ICI +

Externí odkaz: https://doaj.org/article/956b32553a3347c1bdae4e7034beddb4